Publications by authors named "Alfredo Addeo"

77Publications

Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes.

Clin Lung Cancer 2020 Jun 21. Epub 2020 Jun 21.

Medical Oncology, St Salvatore Hospital, L'Aquila, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2020.06.010DOI Listing
June 2020

Is clinical effectiveness in the eye of the beholder during the COVID-19 pandemic?

BMJ Evid Based Med 2020 Jul 9. Epub 2020 Jul 9.

Department of Oncology, Geneva University Hospitals, Geneva, Switzerland

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bmjebm-2020-111423DOI Listing
July 2020

Rethinking the Optimal Duration of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer Throughout the COVID-19 Pandemic.

Front Oncol 2020 12;10:862. Epub 2020 May 12.

Department of Oncology, University Hospital of Geneva (HUG), Geneva, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2020.00862DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7239024PMC
May 2020

The Role of Performance Status in Small-Cell Lung Cancer in the Era of Immune Checkpoint Inhibitors.

Clin Lung Cancer 2020 Apr 30. Epub 2020 Apr 30.

Oncology Department, University Hospital of Geneva, Geneva, Switzerland. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2020.04.006DOI Listing
April 2020

A BRAF new world.

Crit Rev Oncol Hematol 2020 Aug 26;152:103008. Epub 2020 May 26.

Department of Oncology, Geneva University Hospital, Switzerland. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2020.103008DOI Listing
August 2020

Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%.

Cancer Immunol Immunother 2020 05 30. Epub 2020 May 30.

Medical Oncology, St. Salvatore Hospital, L'Aquila, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-020-02613-9DOI Listing
May 2020

COVID-19 and lung cancer: risks, mechanisms and treatment interactions.

J Immunother Cancer 2020 05;8(1)

Oncology, University Hospitals Geneva, Geneve, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jitc-2020-000892DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7246105PMC
May 2020

Reply to Authors.

ESMO Open 2020 05;4(Suppl 2)

Department of Oncology, University Hospital of Geneva, Geneva, Switzerland

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/esmoopen-2020-000809DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7245396PMC
May 2020

KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures.

Cancer Treat Rev 2020 Apr 7;85:101978. Epub 2020 Feb 7.

Oncology Department, University Hospital of Geneva, Switzerland. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2020.101978DOI Listing
April 2020

Comment on Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline Summary.

JCO Oncol Pract 2020 Mar 24;16(3):142-145. Epub 2020 Jan 24.

Vittorio Fusco, MD, Oncology Unit, Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy; Daniele Santini, MD, Oncology Department, Campus Biomedico University, Rome, Italy; Giuseppina Campisi, DDS, MS, Sector of Oral Medicine, Dip DICHIRONS, Università degli Studi di Palermo, Palermo, Italy; Francesco Bertoldo, MD, Medicine Department, Università di Verona, Verona, Italy; Gaetano Lanzetta, MD, Oncology Unit, INI, Grottaferrata, Italy; Toni Ibrahim, MSc, MD, PhD, Osteoncology and Rare Tumors Center. Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy; Oscar Bertetto, MD, Rete Oncologica Department, Torino, Italy; Gianmauro Numico, MD, Oncology Unit, Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy; Alfredo Addeo, MD, Oncology Service, Hopiteaux Universitaires de Geneve, Geneve, Switzerland; Alfredo Berruti, MD, Medical Oncology Unit, University of Brescia, ASST-Spedali Civili, Brescia, Italy; and Giordana Bettini, MD; Giorgia Saia, MD; and Alberto, Regional Center for Prevention, Diagnosis and Treatment of Medication and Radiation-Related Bone Diseases of the Head and Neck, University of Padua, Padua, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.19.00645DOI Listing
March 2020

Immune Checkpoint Inhibitor-Induced Pancreatic Injury: Imaging Findings and Literature Review.

Target Oncol 2020 02;15(1):25-35

Department of Radiology, Azienda Ospedaliera Universitaria Di Cagliari, S.S: 554, km 4500, CAP: 09042, Monserrato, Cagliari, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11523-019-00694-wDOI Listing
February 2020

Circulating tumor DNA and the future of EGFR-mutant lung cancer treatment.

Pharmacogenomics 2019 12;20(18):1255-1257

Department of Clinical & Experimental Medicine, Unit of Clinical Pharmacology & Pharmacogenetics, University Hospital of Pisa, Pisa, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2019-0150DOI Listing
December 2019

Identifying successful biomarkers for patients with non-small-cell lung cancer.

Lung Cancer Manag 2019 Nov 14;8(3):LMT17. Epub 2019 Nov 14.

Department of Oncology, University Hospital of Geneva (HUG), 12052, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/lmt-2019-0009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6891938PMC
November 2019

Poor-Performance Status Assessment of Patients with Non-small Cell Lung Cancer Remains Vague and Blurred in the Immunotherapy Era.

Curr Oncol Rep 2019 11 25;21(12):107. Epub 2019 Nov 25.

Oncology Department, Geneva University Hospital, 4 Rue Gabrielle-Perret-Gentil, 1205, Geneva, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0852-9DOI Listing
November 2019

Circulating biomarkers of response to immunotherapy in cancer treatment.

Pharmacogenomics 2019 12 6;20(18):1247-1249. Epub 2019 Nov 6.

Unit of Clinical Pharmacology & Pharmacogenetics, Department of Clinical & Experimental Medicine, University Hospital of Pisa, 56126, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2019-0117DOI Listing
December 2019

The Activity of Immune Checkpoint Inhibition in KRAS Mutated Non-small Cell Lung Cancer: A Single Centre Experience.

Cancer Genomics Proteomics 2019 Nov-Dec;16(6):577-582

Oncology Department, Geneva University Hospital, Geneva, Switzerland

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/cgp.20160DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6885372PMC
March 2020

Tumor Mutation Burden-From Doubts to Concerns-In Reply.

JAMA Oncol 2019 Oct 24. Epub 2019 Oct 24.

MiRanostics Consulting, Oro Valley, Arizona.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2019.4141DOI Listing
October 2019

Prophylactic cranial irradiation in extensive disease small cell lung cancer: An endless debate.

Crit Rev Oncol Hematol 2019 Nov 12;143:95-101. Epub 2019 Sep 12.

Department of Oncology, University Hospital of Geneva, Geneva, Switzerland. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2019.08.010DOI Listing
November 2019

Measuring tumor mutation burden in cell-free DNA: advantages and limits.

Transl Lung Cancer Res 2019 Aug;8(4):553-555

Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://tlcr.amegroups.com/article/view/27724/22141
Publisher Site
http://dx.doi.org/10.21037/tlcr.2019.03.04DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6749134PMC
August 2019

Diagnosis and Treatment of ALK Aberrations in Metastatic NSCLC.

Curr Treat Options Oncol 2019 09 4;20(10):79. Epub 2019 Sep 4.

Oncology Department, Geneva University Hospital (CH), Rue Gabrielle-Perret-Gentil 4, 1205, Genève, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-019-0675-9DOI Listing
September 2019

New emerging targets in cancer immunotherapy: the role of TIM3.

ESMO Open 2019 12;4(Suppl 3):e000497. Epub 2019 Jun 12.

Oncology, Ospedale Cannizzaro, Catania, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/esmoopen-2019-000497DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6579568PMC
June 2019

Tumor Mutation Burden-From Hopes to Doubts.

JAMA Oncol 2019 Jul;5(7):934-935

Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2019.0626DOI Listing
July 2019

Association of Industry and Academic Sponsorship With Negative Phase 3 Oncology Trials and Reported Outcomes on Participant Survival: A Pooled Analysis.

JAMA Netw Open 2019 05 3;2(5):e193684. Epub 2019 May 3.

Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamanetworkopen.2019.3684DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6512293PMC
May 2019

SABR versus conventional fractionation regimens in NSCLC.

Lancet Oncol 2019 05;20(5):e230

Department of Oncology, San Luigi Hospital University of Turin, Turin, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(19)30175-5DOI Listing
May 2019

Atezolizumab plus Chemotherapy in Small-Cell Lung Cancer.

N Engl J Med 2019 02;380(9):888-889

Hôpitaux Universitaires de Genève, Geneva, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1900123DOI Listing
February 2019

Implementing circulating tumor DNA analysis in a clinical laboratory: A user manual.

Adv Clin Chem 2019;89:131-188. Epub 2019 Jan 28.

Service of Medical Genetics, Diagnostics Department, Geneva University Hospital, Geneva, Switzerland. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00652423183007
Publisher Site
http://dx.doi.org/10.1016/bs.acc.2018.12.004DOI Listing
May 2019

Learning from the past to design better trials in second-line treatment for mesothelioma patients.

Ecancermedicalscience 2018 12;12:881. Epub 2018 Nov 12.

Oncology Department, University Hospital Geneva, 1205 Geneva, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3332/ecancer.2018.881DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6345074PMC
November 2018

Corrigendum to "Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenario" [Crit. Rev. Oncol./Hematol. 122 (February) (2018) 150-156].

Crit Rev Oncol Hematol 2019 Jul 2;139:158. Epub 2018 Nov 2.

Oncology Department, San Luigi Hospital University of Turin, Orbassano, Turin, Italy.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10408428183028
Publisher Site
http://dx.doi.org/10.1016/j.critrevonc.2018.06.018DOI Listing
July 2019

PROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?

Transl Lung Cancer Res 2018 Sep;7(Suppl 3):S287-S289

Division of Medical Oncology, Cannizzaro Hospital, Catania, Italy.

View Article

Download full-text PDF

Source
http://tlcr.amegroups.com/article/view/23044/18289
Publisher Site
http://dx.doi.org/10.21037/tlcr.2018.07.09DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6193904PMC
September 2018

PROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?

Transl Lung Cancer Res 2018 Sep;7(Suppl 3):S283-S286

Division of Medical Oncology, Cannizzaro Hospital, Catania, Italy.

View Article

Download full-text PDF

Source
http://tlcr.amegroups.com/article/view/23046/18287
Publisher Site
http://dx.doi.org/10.21037/tlcr.2018.07.10DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6193909PMC
September 2018

The crucial role of predicting brain metastases development in non-small cell lung cancer patients.

J Thorac Dis 2018 Sep;10(Suppl 26):S3305-S3307

Division of Medical Oncology, Cannizzaro Hospital, Via Messina 829, Catania, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2018.08.95DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6186638PMC
September 2018

Prophylactic Cranial Irradiation in Stage III Non-Small-Cell Lung Cancer: Overall Survival Should Not Necessarily Be the Final End Point.

J Clin Oncol 2018 Oct 22:JCO1800461. Epub 2018 Oct 22.

Alfredo Addeo, Francesca Caparrotti, Cristina Picardi, and Pierre-Yves Dietrich, University Hospital Geneva, Genève, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.18.00461DOI Listing
October 2018

Atezolizumab Treatment of Nonsquamous NSCLC.

N Engl J Med 2018 09;379(12):1187

Hôpitaux Universitaires de Genève, Geneva, Switzerland

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1809195DOI Listing
September 2018

Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients' selection.

Crit Rev Oncol Hematol 2018 Sep 23;129:27-39. Epub 2018 Jun 23.

Medical Oncology Unit, San Gerardo Hospital, Monza, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2018.06.016DOI Listing
September 2018

First-line alectinib for ALK-positive lung cancer: is there room for further improvement?

Drugs Context 2018 10;7:212537. Epub 2018 Jul 10.

Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, Perugia, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7573/dic.212537DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6044318PMC
July 2018

Oral Metronomic Vinorelbine in Advanced Non-small Cell Lung Cancer Patients Unfit for Chemotherapy.

Anticancer Res 2018 Jun;38(6):3689-3697

Department of Biomedical and Biotechnological Sciences, Pathology and Oncology Section, University of Catania, Catania, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.12647DOI Listing
June 2018

Negative phase 3 randomized controlled trials: Why cancer drugs fail the last barrier?

Int J Cancer 2018 10 26;143(8):2079-2081. Epub 2018 Jul 26.

Oncology Department, University Hospital Geneva, Rue Gabrielle-Perret-Gentil 4, Geneva, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.31583DOI Listing
October 2018

Adding an invasive procedure will not necessarily change treatment or outcome of NSCLC patients with preoperative clinical N1 disease.

Eur Respir J 2018 04 4;51(4). Epub 2018 Apr 4.

Division of Medical Oncology, Cannizzaro Hospital, Catania, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1183/13993003.00084-2018DOI Listing
April 2018

Statistical and Clinical Significance in the TERRA Study.

J Clin Oncol 2018 05 20;36(13):1379-1380. Epub 2018 Mar 20.

Paola Di Nardo, Bristol Oncology and Haematology Centre, Bristol, United Kingdom; and Alfredo Addeo, University Hospital Geneva, Geneva, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.77.9595DOI Listing
May 2018

Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenario.

Crit Rev Oncol Hematol 2018 Feb 30;122:150-156. Epub 2017 Dec 30.

Oncology Department, San Luigi Hospital University of Turin, Orbassano, Turin, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2017.12.015DOI Listing
February 2018

Dacomitinib in NSCLC: a positive trial with little clinical impact.

Authors:
Alfredo Addeo

Lancet Oncol 2018 01;19(1):e4

Oncology Department, University Hospital Geneva, 1205 Geneva, Switzerland. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(17)30923-3DOI Listing
January 2018

Exploring the characteristics of patients with mesothelioma who chose active symptom control over chemotherapy as first-line treatment: a prospective, observational, single centre study.

BMC Palliat Care 2017 Dec 8;16(1):71. Epub 2017 Dec 8.

Academic Respiratory Unit, School of Clinical Sciences, University of Bristol, Southmead Hospital, 2nd Floor L&R Building, Bristol, BS10 5NB, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12904-017-0255-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5723074PMC
December 2017

Brain imaging before primary lung cancer resection: a controversial topic.

Ecancermedicalscience 2017 20;11:749. Epub 2017 Jun 20.

Bristol Cancer Institute, University Hospital Trust, Horfield Road, Bristol BS2 8ED, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3332/ecancer.2017.749DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5493439PMC
June 2017

Rushing will not help to choose the best combination.

Lancet Oncol 2017 04;18(4):e186

Department of Hemato-oncology, Nobel Hospital, Kathmandu, Nepal.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(17)30108-0DOI Listing
April 2017

Is There Room for Second-Line Treatment of Pleural Malignant Mesothelioma?

JAMA Oncol 2017 09;3(9):1170-1171

Department of Oncology, Mauriziano Hospital, University of Turin, Turin, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2016.6135DOI Listing
September 2017

Intrathecal Methotrexate and Craniospinal Radiotherapy Can Be an Effective Treatment of Carcinomatous Meningitis in Patients with Breast Cancer: Case Reports.

Case Rep Oncol 2016 Sep-Dec;9(3):586-592. Epub 2016 Oct 12.

Bristol Cancer Institute, University Hospitals Bristol Foundation NHS Trust, Bristol, UK.

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/449448
Publisher Site
http://dx.doi.org/10.1159/000449448DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5118826PMC
October 2016

LUX-Lung 7: is there enough data for a final conclusion?

Lancet Oncol 2016 07;17(7):e266

Bristol Cancer Institute, Bristol BS2 8ED, Somerset, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(16)30116-4DOI Listing
July 2016

Definition and estimation of osteonecrosis of jaw (ONJ), and optimal duration of antiresorptive treatment in bone metastatic cancer patients: supplementary data from the denosumab extension study?

Support Care Cancer 2017 02 9;25(2):345-349. Epub 2016 Mar 9.

Department of Surgical, Oncology and Oral Sciences - Sector of Oral Medicine, Palermo University, Palermo, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00520-016-3147-9DOI Listing
February 2017

Do All High- and Intermediate-Risk Patients With Metastatic Castration-Resistant Prostate Cancer Really Benefit From Abiraterone?

J Clin Oncol 2016 Feb 23;34(4):387. Epub 2015 Nov 23.

Bristol Cancer Institute, Bristol, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.62.8537DOI Listing
February 2016

Optimal Concurrent Chemoradiotherapy Regimen in Non-Small-Cell Lung Cancer: Prospective, Randomized Data Still Required.

J Clin Oncol 2015 Sep 27;33(26):2928. Epub 2015 Jul 27.

Bristol Cancer Centre, Bristol, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.61.7332DOI Listing
September 2015

Inferior mesenteric artery chemoembolization and chemotherapy for advanced rectal cancer: report of a clinical case.

Tumori 2015 Jun 25;101(3):e82-4. Epub 2015 Jun 25.

1 General Surgery Department, SG Bosco Hospital ASL To2, Turin - Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5301/tj.5000270DOI Listing
June 2015

Treatment with ipilimumab: a case report of complete response in a metastatic malignant melanoma patient.

Case Rep Oncol 2013 May 30;6(2):285-8. Epub 2013 May 30.

Departments of Oncology, United Lincolnshire Hospital Trust, Lincoln, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000351834DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3725017PMC
May 2013

A case of abdominal sarcoidosis in a patient with acute myeloid leukemia.

Case Rep Hematol 2013 28;2013:379898. Epub 2013 Feb 28.

Department of Haematology, Pilgrim Hospital, Sibsey Road, Boston, PE21 9QS, Lincolnshire, UK.

View Article

Download full-text PDF

Source
http://www.hindawi.com/journals/crihem/2013/379898/
Publisher Site
http://dx.doi.org/10.1155/2013/379898DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3600231PMC
March 2013

A case of small cell carcinoma of the prostate and review of the literature.

Tumori 2012 May-Jun;98(3):76e-78e

Oncology Department, United Lincolnshire Hospitals NHS Trust, Lincoln and Boston, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1700/1125.12415DOI Listing
October 2012

Phytobezoar in Meckel's diverticulum: A rare cause of small bowel obstruction.

Int J Surg Case Rep 2012 3;3(5):161-3. Epub 2012 Feb 3.

Dept of General and Emergency Surgery, Ospedale SG Bosco, Piazza Donator di Sangue 3, Torino 10159, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijscr.2012.01.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3316763PMC
October 2012

Gefitinib (ZD1839): therapy in selected patients with non-small cell lung cancer (NSCLC)?

Lung Cancer 2008 Jul 19;61(1):73-81. Epub 2008 Feb 19.

Medical Oncology, Centro Oncologico Ematologico Subalpino (C.O.E.S.), Azienda Ospedaliera S. Giovanni Battista, Turin, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2007.12.007DOI Listing
July 2008

Activity of weekly paclitaxel in advanced hormone-refractory prostate cancer.

Am J Clin Oncol 2007 Jun;30(3):234-8

Centro Oncologico ed Ematologico Subalpino, Azienda Ospedaliera San Giovanni Battista, Corso Bramante 88, 10126 Torino, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.coc.0000256706.16313.49DOI Listing
June 2007

Second-line chemotherapy with weekly paclitaxel and gemcitabine in patients with small-cell lung cancer pretreated with platinum and etoposide: a single institution phase II trial.

Cancer Chemother Pharmacol 2006 Aug 6;58(2):203-9. Epub 2005 Dec 6.

Oncologia Medica, Centro Oncologico Ematologico Subalpino, Azienda Ospedaliera Molinette, Via Cherasco 15, 10126 Torino, Italy.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00280-005-0157-6
Publisher Site
http://dx.doi.org/10.1007/s00280-005-0157-6DOI Listing
August 2006

Human pancreatic carcinoma cells secrete bioactive interleukin-18 after treatment with 5-fluorouracil: implications for anti-tumor immune response.

Cancer Biol Ther 2005 Feb 2;4(2):231-41. Epub 2005 Feb 2.

Department of Gastroenterology and Clinical Nutrition, Azienda Ospedaliera San Giovanni Battista, Molinette, Turin, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cbt.4.2.1476DOI Listing
February 2005

A phase II trial of weekly paclitaxel and gemcitabine in non-small cell lung cancer patients previously treated with platinum and vinorelbine.

Anticancer Res 2004 Jul-Aug;24(4):2567-72

Oncologia Medica, Centro Oncologico Ematologico Subalpino, Azienda Ospedaliera Molinette, Torino, Italy.

View Article

Download full-text PDF

Source
September 2004